Is Exagen Stock a Good Investment?
Exagen Investment Advice | XGN |
- Examine Exagen's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Exagen's leadership team and their track record. Good management can help Exagen navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Exagen's business and its evolving consumer preferences.
- Compare Exagen's performance and market position to its competitors. Analyze how Exagen is positioned in terms of product offerings, innovation, and market share.
- Check if Exagen pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Exagen's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Exagen Inc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Exagen Inc is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Very regressive towards the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Exagen Stock
Researching Exagen's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 28.0% of the company outstanding shares are owned by insiders. The company recorded a loss per share of 0.83. Exagen Inc had not issued any dividends in recent years.
To determine if Exagen is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Exagen's research are outlined below:
| Exagen Inc generated a negative expected return over the last 90 days | |
| Exagen Inc has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 55.64 M. Reported Net Loss for the year was (15.12 M) with profit before taxes, overhead, and interest of 33.11 M. | |
| Exagen Inc has about 76.39 M in cash with (13.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.7, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 28.0% of the company outstanding shares are owned by insiders | |
| Latest headline from Macroaxis: Are Exagen unfluctuating technical and fundamental indicators contributing to the recent decline |
Exagen Quarterly Cost Of Revenue |
|
Exagen uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Exagen Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Exagen's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Exagen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Exagen's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-03-17 | 2024-12-31 | -0.24 | -0.2 | 0.04 | 16 | ||
2020-05-11 | 2020-03-31 | -0.49 | -0.44 | 0.05 | 10 | ||
2021-08-09 | 2021-06-30 | -0.44 | -0.38 | 0.06 | 13 | ||
2022-03-22 | 2021-12-31 | -0.5 | -0.42 | 0.08 | 16 | ||
2020-03-25 | 2019-12-31 | -0.37 | -0.27 | 0.1 | 27 | ||
2024-03-18 | 2023-12-31 | -0.43 | -0.31 | 0.12 | 27 | ||
2023-05-15 | 2023-03-31 | -0.56 | -0.44 | 0.12 | 21 | ||
2020-11-10 | 2020-09-30 | -0.47 | -0.34 | 0.13 | 27 |
Exagen Target Price Consensus
Exagen target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Exagen's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 6 | Strong Buy |
Most Exagen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Exagen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Exagen Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationExagen Target Price Projection
Exagen's current and average target prices are 3.69 and 6.75, respectively. The current price of Exagen is the price at which Exagen Inc is currently trading. On the other hand, Exagen's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Exagen Target Price
Exagen Analyst Ratings
Exagen's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Exagen stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Exagen's financials, market performance, and future outlook by experienced professionals. Exagen's historical ratings below, therefore, can serve as a valuable tool for investors.Know Exagen's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Exagen is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Exagen Inc backward and forwards among themselves. Exagen's institutional investor refers to the entity that pools money to purchase Exagen's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-12-31 | 98.1 K | Palumbo Wealth Management Llc | 2024-12-31 | 86.7 K | Ubs Group Ag | 2024-12-31 | 64.2 K | Nantahala Capital Management, Llc | 2024-12-31 | 62.1 K | Penbrook Management Llc | 2024-12-31 | 44.6 K | Wasatch Advisors Lp | 2024-12-31 | 43 K | Creative Planning Inc | 2024-12-31 | 35.5 K | State Street Corp | 2024-12-31 | 33.7 K | Blackrock Inc | 2024-12-31 | 33.4 K | Rtw Investments, Llc | 2024-12-31 | 1.5 M | Cowen And Company, Llc | 2024-09-30 | 891.4 K |
Exagen's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 67.12 M.Market Cap |
|
Exagen's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.36) | |
| Return On Capital Employed | (0.44) | (0.46) | |
| Return On Assets | (0.34) | (0.36) | |
| Return On Equity | (1.58) | (1.66) |
Determining Exagen's profitability involves analyzing its financial statements and using various financial metrics to determine if Exagen is a good buy. For example, gross profit margin measures Exagen's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Exagen's profitability and make more informed investment decisions.
Evaluate Exagen's management efficiency
Exagen Inc has Return on Asset of (0.1677) % which means that on every $100 spent on assets, it lost $0.1677. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.9378) %, meaning that it generated no profit with money invested by stockholders. Exagen's management efficiency ratios could be used to measure how well Exagen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 20th of March 2025, Return On Tangible Assets is likely to drop to -0.36. In addition to that, Return On Capital Employed is likely to drop to -0.46. At this time, Exagen's Net Tangible Assets are very stable compared to the past year. As of the 20th of March 2025, Fixed Asset Turnover is likely to grow to 9.29, while Non Currrent Assets Other are likely to drop about 534 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.52 | 0.55 | |
| Tangible Book Value Per Share | 0.52 | 0.55 | |
| Enterprise Value Over EBITDA | (5.00) | (5.26) | |
| Price Book Value Ratio | 7.82 | 8.21 | |
| Enterprise Value Multiple | (5.00) | (5.26) | |
| Price Fair Value | 7.82 | 8.21 | |
| Enterprise Value | 55.8 M | 29.5 M |
At Exagen Inc, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 1.404 |
Basic technical analysis of Exagen Stock
As of the 20th of March, Exagen shows the Coefficient Of Variation of (5,773), mean deviation of 5.08, and Standard Deviation of 8.32. In respect to fundamental indicators, the technical analysis model provides you with a way to check existing technical drivers of Exagen, as well as the relationship between them.Exagen's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exagen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exagen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Exagen insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Exagen's Outstanding Corporate Bonds
Exagen issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Exagen Inc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Exagen bonds can be classified according to their maturity, which is the date when Exagen Inc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| US30063PAB13 Corp BondUS30063PAB13 | View | |
| US30063PAC95 Corp BondUS30063PAC95 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Exagen's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Exagen's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 5.08 | |||
| Coefficient Of Variation | (5,773) | |||
| Standard Deviation | 8.32 | |||
| Variance | 69.17 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0328 | |||
| Total Risk Alpha | 0.5481 | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 42.16 | |||
| Value At Risk | (11.56) | |||
| Potential Upside | 15.86 | |||
| Skewness | 1.19 | |||
| Kurtosis | 5.04 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 5.08 | |||
| Coefficient Of Variation | (5,773) | |||
| Standard Deviation | 8.32 | |||
| Variance | 69.17 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0328 | |||
| Total Risk Alpha | 0.5481 | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 42.16 | |||
| Value At Risk | (11.56) | |||
| Potential Upside | 15.86 | |||
| Skewness | 1.19 | |||
| Kurtosis | 5.04 |
Consider Exagen's intraday indicators
Exagen intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Exagen stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Exagen Corporate Filings
8K | 11th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 4th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 25th of February 2025 Other Reports | ViewVerify | |
| 29th of January 2025 Other Reports | ViewVerify |
Exagen Stock media impact
Far too much social signal, news, headlines, and media speculation about Exagen that are available to investors today. That information is available publicly through Exagen media outlets and privately through word of mouth or via Exagen internal channels. However, regardless of the origin, that massive amount of Exagen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Exagen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Exagen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Exagen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Exagen alpha.
Exagen Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Exagen can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Exagen Corporate Management
| Jeffrey Black | Chief Officer | Profile | |
| Debra Zack | Chief Officer | Profile | |
| John Wegener | Senior Marketing | Profile | |
| Ryan Douglas | Investors Officer | Profile | |
| Mark Hazeltine | Chief Officer | Profile | |
| MingChou Lee | Chief Officer | Profile |
Already Invested in Exagen Inc?
The danger of trading Exagen Inc is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Exagen is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Exagen. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Exagen Inc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Exagen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Exagen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Exagen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Exagen Inc Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets | Return On Equity |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Exagen's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.